Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 8/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.34 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 5/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22470161 | 0.89 | KCNN4 (0.59) | KCNN4TAS1R3TAS1R1TAS1R2RORC | |
| SCHEMBL29353607 | 0.88 | KCNN4 (0.72) | KCNN4TAS1R3TAS1R1TAS1R2RORC | |
| SCHEMBL29359283 | 0.85 | KCNN4 (0.72) | KCNN4RORCAR | |
| SCHEMBL29356955 | 0.84 | KCNN4 (0.65) | KCNN4TAS1R3TAS1R1TAS1R2RORC | |
| SCHEMBL22470492 | 0.83 | KCNN4 (0.72) | KCNN4TAS1R3TAS1R1TAS1R2NOTUM | |
| SCHEMBL29357409 | 0.83 | KCNN4 (0.72) | KCNN4TAS1R3TAS1R1TAS1R2NOTUM | |
| SCHEMBL28663475 | 0.82 | KCNN4 (0.58) | KCNN4TAS1R3TAS1R1TAS1R2NOTUM | |
| SCHEMBL29356985 | 0.81 | KCNN4 (0.66) | KCNN4RORCAR | |
| SCHEMBL29356770 | 0.77 | KCNN4 (0.76) | KCNN4TAS1R3TAS1R1TAS1R2RORC | |
| SCHEMBL22470482 | 0.77 | KCNN4 (0.60) | KCNN4TAS1R3TAS1R1TAS1R2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049054-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA AS (DK) | 2026-02-19 | — | — | US | disclosed |
| US-12391644-B2 | Potassium channel inhibitors | SANIONA A/S (DK) | 2025-08-19 | — | — | US | disclosed |
| EP-3941903-B1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA AS (DK) | 2025-07-16 | — | — | EP | disclosed |
| US-20240368077-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA AS (DK) | 2024-11-07 | — | — | US | disclosed |
| US-12006289-B2 | Potassium channel inhibitors | SANIONA A/S (DK) | 2024-06-11 | — | — | US | disclosed |
| US-20220169602-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA A/S (DK) | 2022-06-02 | — | — | US | disclosed |
| EP-3941903-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | Saniona A/S (DK) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391644-B2 | Potassium channel inhibitors | KCNJ2, KCNN2, KCNN1 | KCNN4 48/4885TAS1R3 2145/4885TAS1R1 2182/4885 |
| US-20240368077-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN2, KCNJ2, KCNN1 | KCNN4 57/4885TAS1R3 1668/4885TAS1R1 1703/4885 |
| US-20220169602-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN2, KCNJ2, KCNN1 | KCNN4 57/4885TAS1R3 1668/4885TAS1R1 1703/4885 |
| US-12006289-B2 | Potassium channel inhibitors | KCNJ2, KCNN2, KCNN1 | KCNN4 48/4885TAS1R3 2145/4885TAS1R1 2182/4885 |
| US-20260049054-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SCN10A, KCNK10, KCNJ2 | KCNN4 43/4885TAS1R3 580/4885TAS1R1 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.